MCID: KLD004
MIFTS: 45

Keloid Disorder

Categories: Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Keloid Disorder

Summaries for Keloid Disorder

MalaCards based summary: Keloid Disorder, also known as keloid, is related to scleroderma, familial progressive and peyronie's disease. An important gene associated with Keloid Disorder is H19 (H19 Imprinted Maternally Expressed Transcript), and among its related pathways/superpathways are Wnt / Hedgehog / Notch and DNA damage response (only ATM dependent). The drugs Lidocaine and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and bone marrow, and related phenotypes are digestive/alimentary and skeleton

Wikipedia: 75 Keloid, also known as keloid disorder and keloidal scar, is the formation of a type of scar which,... more...

Related Diseases for Keloid Disorder

Diseases related to Keloid Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 344)
# Related Disease Score Top Affiliating Genes
1 scleroderma, familial progressive 29.8 CD36 BMP6
2 peyronie's disease 29.6 TGFB1 SMAD3
3 hypertrophic scars 29.4 TGFB1 CD36 BMP6
4 bullous keratopathy 29.3 TGFB1 BMP6
5 gingival overgrowth 29.2 TGFB1 CD36
6 osteogenic sarcoma 28.7 TGFB1 H19 CD36 BMP6
7 osteoporosis 28.5 TGFB1 SMAD3 CD36 BMP6
8 pulmonary fibrosis 28.3 TGFB1 SMAD3 SERPINH1 CD36 BMP6
9 interstitial lung disease 2 28.1 TGFB1 SMAD3 SERPINH1 CD36 BMP6
10 premature aging syndrome, penttinen type 11.5
11 x-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome 11.3
12 frontometaphyseal dysplasia 2 11.1
13 warburg-cinotti syndrome 11.1
14 overgrowth syndrome 10.4
15 skin benign neoplasm 10.4
16 systemic scleroderma 10.3
17 down syndrome 10.3
18 chromosome 2q35 duplication syndrome 10.2
19 dilution, pigmentary 10.2
20 telangiectasis 10.2
21 folliculitis 10.2
22 blastomycosis 10.1
23 dermatitis 10.1
24 dermatofibrosarcoma protuberans 10.1
25 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.1
26 insulin-like growth factor i 10.1
27 dermatitis, atopic 10.1
28 immunodeficiency, common variable, 10 10.1
29 tatton-brown-rahman syndrome 10.1
30 helix syndrome 10.1
31 skin atrophy 10.1
32 localized scleroderma 10.1
33 herpes zoster 10.1
34 47 xxx syndrome 10.1
35 dupuytren contracture 10.0
36 epidermoid cysts 10.0
37 multiple pterygium syndrome, escobar variant 10.0
38 fanconi anemia, complementation group e 10.0
39 leiomyoma 10.0
40 keloid formation 10.0
41 skin disease 10.0
42 corneal neovascularization 10.0 H19 CD36
43 ureteral disease 10.0 TGFB1 SMAD3
44 obstructive nephropathy 10.0 TGFB1 SMAD3
45 pelvic organ prolapse 10.0 TGFB1 SMAD3
46 pneumoconiosis 10.0 TGFB1 H19
47 hyaline fibromatosis syndrome 10.0
48 syphilis 10.0
49 tertiary syphilis 10.0
50 leiomyoma, uterine 9.9

Graphical network of the top 20 diseases related to Keloid Disorder:



Diseases related to Keloid Disorder

Symptoms & Phenotypes for Keloid Disorder

MGI Mouse Phenotypes related to Keloid Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.35 BMP6 CD36 SERPINH1 SMAD3 TGFB1
2 skeleton MP:0005390 9.02 BMP6 CD36 SERPINH1 SMAD3 TGFB1

Drugs & Therapeutics for Keloid Disorder

Drugs for Keloid Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
4
Povidone-iodine Approved Phase 4 25655-41-8
5
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
6
Ethanol Approved Phase 4 64-17-5 702
7
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
8
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
9
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
10
Tocopherol Approved, Investigational Phase 4 1406-66-2
11
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
12
Prilocaine Approved Phase 4 721-50-6 4906
13
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
14
Fluorouracil Approved Phase 4 51-21-8 3385
15
Bleomycin Approved, Investigational Phase 4 9041-93-4, 11056-06-7 5360373
16
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
17
Verapamil Approved Phase 4 152-11-4, 52-53-9 2520
18
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 4 59-02-9, 10191-41-0 2116 14985
19
Tocotrienol Investigational Phase 4 6829-55-6 9929901
20 Trace Elements Phase 4
21 Micronutrients Phase 4
22 Antineoplastic Agents, Hormonal Phase 4
23 Antiemetics Phase 4
24 Anesthetics Phase 4
25 Gastrointestinal Agents Phase 4
26 Lidocaine, Prilocaine Drug Combination Phase 4
27 Anesthetics, Local Phase 4
28 Vitamins Phase 4
29 Antioxidants Phase 4
30 Hydrocortisone 17-butyrate 21-propionate Phase 4
31 Protective Agents Phase 4
32 Tocotrienols Phase 4
33 Tocopherols Phase 4
34 Sodium Channel Blockers Phase 4
35 Diuretics, Potassium Sparing Phase 4
36 Chlorhexidine gluconate Phase 4
37 Neurotransmitter Agents Phase 4
38
abobotulinumtoxinA Phase 4
39 Botulinum Toxins, Type A Phase 4
40 Botulinum Toxins Phase 4
41 Cholinergic Agents Phase 4
42 Antimetabolites Phase 4
43 Pharmaceutical Solutions Phase 4
44 Anti-Bacterial Agents Phase 4
45 Antibiotics, Antitubercular Phase 4
46 Immunosuppressive Agents Phase 4
47 Immunologic Factors Phase 4
48 Hormones Phase 4
49 Hormone Antagonists Phase 4
50
Triamcinolone hexacetonide Phase 4

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 Pilot Study to Evaluate Clinical Outcomes With the Use of Biovance, a Dehydrated Decellularized Human Amnion Membrane Allograft, Following Keloid Revision Surgery Unknown status NCT02521402 Phase 4
2 Keloid Scarring:A Randomized Clinical and Laboratory Based Study on the Treatment and Differentiation Factors of the Local Disease Unknown status NCT01295099 Phase 4 5- fluorouracil;Triamcinolone
3 Intralesional Injection of Steroids and/or Botulinum Toxin Type A in Hypertrophic Scars and Keloids for Pain Improvement Unknown status NCT03982862 Phase 4 Triamcinolone;Lidocaine;Botulinum toxin A
4 Combined Surgical Excision and Intralesional Steroid Injection for Prevention of Post Caesarean Keloid Recurrence.A Randomized Controlled Trial. Completed NCT03239964 Phase 4 Dexamethasone
5 A Prospective, Randomized, Investigator-blinded, Placebo-controlled, Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars Completed NCT00754247 Phase 4 0.5% hydrocortisone, silicone, vitamin E lotion;Onion extract gel;Cetearyl alcohol lotion
6 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Completed NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
7 Pilot Study of a Novel 532nm KTP Laser for the Treatment of Fresh Surgical Scars Completed NCT01789346 Phase 4
8 A Double Blind Randomized Controlled Trial Comparing the Efficacy of 7% Lidocaine / 7% Tetracaine Cream Versus 2,5% Lidocaine / 2,5% Prilocaine Cream for Local Anaesthesia During Laser Treatment of Acne Keloidalis Nuchae and Tattoo Removal Completed NCT02372786 Phase 4 2,5% lidocaine / 2,5% prilocaine cream;7% lidocaine / 7% tetracaine cream
9 The Efficacy of Laser Assisted Hair Removal in the Treatment of Acne Keloidalis Nuchae; a Pilot Study Completed NCT01548898 Phase 4
10 Immediate Injection of Botulinum Toxin Type A After Keloid Scar Revision to Prevent Keloid Recurrence: a Prospective, Split-scar, Double-blind, Randomized Controlled Study Recruiting NCT05072821 Phase 4 Botulinum Toxin Type A Injection [Botox];0.9% Sodium Chloride Injection
11 Defining Reversal of Keloid Lesions by Th2 Targeting With Dupilumab Treatment Recruiting NCT04988022 Phase 4 Dupilumab;Placebo
12 A Prospective Triple-Blinded Single-Center Study of Laser-Assisted 5-Fluorouracil Versus Laser-Assisted Corticosteroid Treatment for Keloids Recruiting NCT04786210 Phase 4
13 Intralesional Bleomycin Treatment of Keloids Using an Electronic Pneumatic Jet Injector: a Double-blind Randomized, Placebo-controlled Trial With Split-lesion Design Active, not recruiting NCT04582305 Phase 4 Bleomycin;Normal saline
14 Assessment of Verapamil as an Adjunct for Prevention of Keloid Recurrence After Surgical Removal Terminated NCT01720056 Phase 4 Verapamil;Kenalog 10
15 Topical Treatment With Glucocorticoids to Prevent Hypertrophic Scars and Keloid Due to Central Venous Access in Children Unknown status NCT01113125 Phase 3 Betamethason-17-valerate and fusidic acid;Fusidic Acid
16 Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars: 3-arm Trial Unknown status NCT02823236 Phase 3 Topical Pirfenidone;Triamcinolone + Pirfenidone;Intralesional Triamcinolone
17 Effect of Infra-red Diode Laser on Improvement of Surgical Scar and on the Prevention of Excised Keloids Recurrence-Pilot Study Unknown status NCT01158196 Phase 3
18 Assessing the Effectiveness of Protescal In Preventing Post Caesarean Section Hypertrophic Scar and Keloid Completed NCT04951869 Phase 2, Phase 3 Protescal gel
19 Silicone Gel Versus Onion Extract Gel as Prevention for Postsurgical Scars: a Randomized Controlled Trial Completed NCT01861119 Phase 3 Silicone gel Kelo-cort™;;Onion extract gel Contractubex™
20 Efficacy of CICATRIX (Asian Gotu Kola or Pennywort) in the Treatment of Hypertrophic Scars and Keloids Scars. Completed NCT00993005 Phase 3
21 Efficacy and Safety of Duobrii in the Management of Acne Keloidalis Nuchae (AKN) Recruiting NCT05608499 Phase 3 Duobrii;Placebo;Bryhali
22 Intra-lesional ACE Inhibitor for Treatment of Keloid Scars Not yet recruiting NCT05259137 Phase 2, Phase 3 Intralesional enalaprilat injection
23 Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid Regression: Immunohistochemistry, Histopathology and Imaging Study Unknown status NCT04326959 Phase 1, Phase 2
24 Post-operative Topical Administration of Fibrosis Inhibiting Compound FS2 in a Double-blind, Randomized, Vehicle-controlled Study Evaluating the Safety and Prevention of Cutaneous Scarring in Skin Grafts and Donor Sites. Unknown status NCT04186273 Phase 2 Fibrosis-Inhibiting-Compound-FS2
25 The Effectiveness of UVB Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study Completed NCT00129428 Phase 1, Phase 2
26 A Multi-Center, Prospective, Randomized, Single-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults Completed NCT02079168 Phase 2 RXI-109;Placebo
27 A Prospective, Randomized, Comparative Feasibility Study Evaluating the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181 Adjunctive to Surgical Scar Revision Completed NCT01446770 Phase 2
28 Evaluation the Safety and Efficacy of the Treatment of Scars and Cutis Laxa Syndrome With the Use of Autologous (Fresh and Stored) Stem Cells Isolated From Adipose Tissue. Completed NCT03887208 Phase 1, Phase 2
29 Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention Completed NCT03795116 Phase 2
30 A Single-centre, Double Blind, Randomised, Exploratory Study to Explore the Efficacy and Safety of Juvista 250ng/100µL/Linear cm When Administered Following Excision of Ear Lobe Keloids. Completed NCT00836147 Phase 1, Phase 2 Avotermin (Juvista);Placebo
31 A Single-centre, Double Blind, Randomised, Tolerance Study to Investigate the Safety of Juvista 500ng/100µL/Linear cm When Administered Following Excision of Ear Lobe Keloids. Completed NCT00710333 Phase 1, Phase 2 Avotermin;placebo
32 Autologous Adipose Derived Stem Cell Transplantation in the Treatment of Keloids. A Pilot Randomized Controlled Trial Completed NCT04553159 Phase 2
33 A Single-centre, Double Blind, Randomised, Rising Dose Tolerance Study to Investigate the Safety of Juvista When Administered Following Excision of Ear Lobe Keloids. Completed NCT00469235 Phase 1, Phase 2 Avotermin
34 A Prospective, Randomized, Controlled Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids Completed NCT00587587 Phase 1, Phase 2
35 A Phase 2, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of MRG-201 Following Intradermal Injection in Subjects With a History of Keloids Completed NCT03601052 Phase 2 Remlarsen;Placebo
36 A Pilot Phase 2a Blinded, Placebo Controlled, Multicenter Parallel Group, Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of AZX100 Drug Product Following Excision of Keloids Completed NCT00825916 Phase 2 AZX100 Drug Product;Placebo
37 A Pilot Phase 2a Blinded, Placebo Controlled, Multicenter Parallel Group, Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloids Completed NCT00892723 Phase 2 AZX100 Drug Product;Placebo
38 A Phase 2, Multi-Center, Randomized, Multiple Arm, Controlled Pilot Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Reducing Post- Keloidectomy Keloid Recurrence Recruiting NCT04844840 Phase 2 STP705
39 Efficacy of Autologous Adipose Derived Stromal Vascular Fraction in the Treatment of Keloids Recruiting NCT04391621 Phase 2 Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1
40 An Open-label Proof of Concept Study Regarding the Efficacy and Safety of Dupilumab in the Treatment of Keloids Recruiting NCT05128383 Phase 2 Dupilumab
41 Open-label, Single-arm Pilot Study of the Effects of Topical 5% Imiquimod Cream on Preventing Keloid Recurrence After Surgical Keloidectomy Terminated NCT03760250 Phase 2 Imiquimod 5% cream
42 A Post-shave Keloid Recurrence Study in Two Parts: A Biomarker Assessment Followed by a Randomized, Double-blind, Placebo Controlled Evaluation of Safety, Tolerability, and Efficacy of QAX576 Terminated NCT00987545 Phase 2 QAX576;QAX576 placebo
43 A Therapeutic Trial of Intralesional Bevacizumab in Patients With Non-pedunculated Keloids Terminated NCT01408953 Phase 2
44 Phase II Trial of Sorafenib in Patients With Extensive Keloids Terminated NCT01425216 Phase 2 Sorafenib
45 Within-subject Randomized Clinical Trial Comparing Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars Withdrawn NCT02546076 Phase 2
46 EBIRE: Phase 1 Study of High Fluence LED-Red Light in Fitzpatrick Skin Types I to III Unknown status NCT03433222 Phase 1
47 Calcium Electroporation for the Treatment of Keloids Completed NCT01941914 Phase 1 Calcium chloride
48 Phase I Study of High Fluence Light Emitting Diode-Red Light (LED-RL) in Human Skin Completed NCT02630303 Phase 1
49 The Safety of Topically Delivered FS2 in Humans. Phase 1 Clinical Trial Completed NCT02340325 Phase 1 Acute Application of kynurenic acid cream;Chronic application of kynurenic acid cream
50 An Exploratory Study to Evaluate the Safety and Efficacy of Intradermal Administration of AIV001 Aqueous Suspension on Scar Formation and Keloid Recurrence Following Keloidectomy Recruiting NCT04827875 Phase 1 AIV001

Search NIH Clinical Center for Keloid Disorder

Genetic Tests for Keloid Disorder

Genetic tests related to Keloid Disorder:

# Genetic test Affiliating Genes
1 Keloid 28

Anatomical Context for Keloid Disorder

Organs/tissues related to Keloid Disorder:

MalaCards : Skin, Liver, Bone Marrow, Endothelial, Breast, Smooth Muscle, Lymph Node

Publications for Keloid Disorder

Articles related to Keloid Disorder:

(show top 50) (show all 3714)
# Title Authors PMID Year
1
Effect of the abrogation of TGF-beta1 by antisense oligonucleotides on the expression of TGF-beta-isoforms and their receptors I and II in isolated fibroblasts from keloid scars. 53 62
20428796 2010
2
Syndecan-2 and decorin: proteoglycans with a difference--implications in keloid pathogenesis. 53 62
20386290 2010
3
Mechanisms of transforming growth factor beta(1)/Smad signalling mediated by mitogen-activated protein kinase pathways in keloid fibroblasts. 53 62
19772524 2010
4
Topical tamoxifen therapy in hypertrophic scars or keloids in burns. 53 62
19636578 2010
5
Keloid scarring: new treatments ahead. 53 62
20096165 2009
6
Elastic fiber assembly is disrupted by excessive accumulation of chondroitin sulfate in the human dermal fibrotic disease, keloid. 53 62
19879246 2009
7
Human embryonic stem cell-derived mesoderm-like epithelium transitions to mesenchymal progenitor cells. 53 62
19196144 2009
8
Effect of camptothecin on collagen synthesis in fibroblasts from patients with keloid. 53 62
19546682 2009
9
[Expression of Smads in keloid scarring]. 53 62
19781253 2009
10
Low decorin expression along with inherent activation of ERK1,2 in ear lobe keloids. 53 62
19268470 2009
11
[The effect of tunicamycin on Fas protein expression and its function in fibroblasts from hypertrophic scar and keloid]. 53 62
19803206 2009
12
Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP Kinase 2 inhibitor. 53 62
19289101 2009
13
Promoted activation of matrix metalloproteinase (MMP)-2 in keloid fibroblasts and increased expression of MMP-2 in collagen bundle regions: implications for mechanisms of keloid progression. 53 62
19438747 2009
14
Cytokine profiling and Stat3 phosphorylation in epithelial-mesenchymal interactions between keloid keratinocytes and fibroblasts. 53 62
19037237 2009
15
Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts. 53 62
19120328 2009
16
Keloid scarring: bench and bedside. 53 62
19360429 2009
17
[Expression and function of sphingosine kinases 1 and 2 in human keloid fibroblasts]. 53 62
19567073 2009
18
Cell permeant peptide analogues of the small heat shock protein, HSP20, reduce TGF-beta1-induced CTGF expression in keloid fibroblasts. 53 62
18787533 2009
19
Basic fibroblast growth factor: a potential new therapeutic tool for the treatment of hypertrophic and keloid scars. 53 62
19071002 2009
20
Keloidal basal cell carcinoma: not a distinctive clinicopathological entity. 53 62
18795924 2009
21
[Comparison of the mechanisms of intralesional steroid, interferon or verapamil injection in the treatment of proliferative scars]. 53 62
19408724 2009
22
Keloid banding using suture ligature: a novel technique and review of literature. 53 62
18978483 2008
23
Adenoviral overexpression and small interfering RNA suppression demonstrate that plasminogen activator inhibitor-1 produces elevated collagen accumulation in normal and keloid fibroblasts. 53 62
18832570 2008
24
Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid fibroblasts via inhibition of the STAT3-signaling pathway. 53 62
18463684 2008
25
DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts. 53 62
18406579 2008
26
The use of corticosteroids to treat keloids: a review. 53 62
18611924 2008
27
[The expression of fibrillin 1 in pathologic scars and its significance]. 53 62
19119630 2008
28
TGF-beta1 antisense therapy modulates expression of matrix metalloproteinases in keloid-derived fibroblasts. 53 62
18575776 2008
29
Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts. 53 62
17943180 2008
30
Transforming growth factor-beta1-antisense modulates the expression of hepatocyte growth factor/scatter factor in keloid fibroblast cell culture. 53 62
18087663 2008
31
[The role of cell pathway in apoptosis of fibroblasts from proliferative scar induced by steroid or IFN]. 53 62
18437985 2008
32
Targeting of Sp1 transcription factor: a novel therapeutic approach for keloids, an in vitro analysis. 53 62
18031462 2007
33
Increased CCN2 transcription in keloid fibroblasts requires cooperativity between AP-1 and SMAD binding sites. 53 62
17968183 2007
34
Transforming growth factor beta (TGFbeta) and keloid disease. 53 62
17660136 2007
35
Effect of heat shock protein 47 on collagen accumulation in keloid fibroblast cells. 53 62
17535221 2007
36
Fas-mediated apoptotic signal transduction in keloid and hypertrophic scar. 53 62
17440345 2007
37
[The expression of periostin in hyperplasic scars and the relations to TGF-beta1 and its receptors]. 53 62
17649947 2007
38
Flashlamp pulsed-dye laser suppressed TGF-beta1 expression and proliferation in cultured keloid fibroblasts is mediated by MAPK pathway. 53 62
17457842 2007
39
[Discoidin domain receptors (DDRs) expression in pathological scar fibroblast formation]. 53 62
17554880 2007
40
Exogenous nitric oxide stimulated collagen type I expression and TGF-beta1 production in keloid fibroblasts by a cGMP-dependent manner. 53 62
17052928 2007
41
Induction of TIMP-1 and HSP47 synthesis in primary keloid fibroblasts by exogenous nitric oxide. 53 62
17145168 2007
42
Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts. 53 62
17889631 2007
43
Green tea extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/AkT signaling pathways. 53 62
16841034 2006
44
Modulation of collagen synthesis in keloid fibroblasts by silencing Smad2 with siRNA. 53 62
17051103 2006
45
[Expressions of TGF-betaR I, Smad2, Smad3 and Smad7 in keloids]. 53 62
17144456 2006
46
Upregulation of secretory connective tissue growth factor (CTGF) in keratinocyte-fibroblast coculture contributes to keloid pathogenesis. 53 62
16705627 2006
47
Upregulation of TGF-beta1 expression may be necessary but is not sufficient for excessive scarring. 53 62
16498396 2006
48
Elevated prolidase activity in keloids: correlation with type I collagen turnover. 53 62
16634881 2006
49
[Relationship between the proliferation and immunoinduction of epithelial cells and the destruction of hair follicles and sebaceous glands in keloids]. 53 62
16736611 2006
50
P38 MAP kinase mediates transforming growth factor-beta2 transcription in human keloid fibroblasts. 53 62
16467496 2006

Variations for Keloid Disorder

Expression for Keloid Disorder

Search GEO for disease gene expression data for Keloid Disorder.

Pathways for Keloid Disorder

Pathways related to Keloid Disorder according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1 11.69 TGFB1 SMAD3 BMP6
2 11.64 TGFB1 SMAD3
3
Show member pathways
11.62 TGFB1 SMAD3
4 11.6 TGFB1 SMAD3
5 11.59 TGFB1 SMAD3
6 11.58 TGFB1 BMP6
7
Show member pathways
11.57 TGFB1 SMAD3
8
Show member pathways
11.56 TGFB1 SMAD3
9
Show member pathways
11.54 TGFB1 SMAD3
10 11.48 TGFB1 BMP6
11 11.42 TGFB1 SMAD3
12 11.41 TGFB1 SMAD3
13 11.38 TGFB1 SMAD3
14 11.28 TGFB1 SMAD3
15 11.26 TGFB1 BMP6
16 11.23 SMAD3 TGFB1
17
Show member pathways
11.23 TGFB1 SERPINH1 BMP6
18 11.2 TGFB1 SMAD3
19 11.18 TGFB1 SMAD3
20 11.06 TGFB1 SMAD3 BMP6
21 10.99 TGFB1 SMAD3
22 10.88 TGFB1 SMAD3
23 10.85 TGFB1 SMAD3
24
Show member pathways
10.8 TGFB1 SMAD3
25 10.67 TGFB1 SMAD3 SERPINH1
26 10.55 TGFB1 SMAD3

GO Terms for Keloid Disorder

Biological processes related to Keloid Disorder according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.15 TGFB1 SMAD3 CD36 BMP6
2 negative regulation of gene expression GO:0010629 10.02 TGFB1 SMAD3 CD36
3 positive regulation of epithelial to mesenchymal transition GO:0010718 9.92 TGFB1 SMAD3
4 positive regulation of nitric oxide biosynthetic process GO:0045429 9.91 SMAD3 CD36
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.88 TGFB1 CD36 BMP6
6 positive regulation of chondrocyte differentiation GO:0032332 9.87 SMAD3 BMP6
7 MAPK cascade GO:0000165 9.83 TGFB1 SMAD3 CD36
8 extrinsic apoptotic signaling pathway GO:0097191 9.82 TGFB1 SMAD3
9 positive regulation of miRNA transcription GO:1902895 9.81 TGFB1 SMAD3
10 positive regulation of protein secretion GO:0050714 9.81 TGFB1 BMP6
11 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.8 TGFB1 BMP6
12 positive regulation of protein import into nucleus GO:0042307 9.78 SMAD3 TGFB1
13 ureteric bud development GO:0001657 9.77 SMAD3 TGFB1
14 endoderm development GO:0007492 9.77 TGFB1 SMAD3
15 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.76 TGFB1 SMAD3
16 BMP signaling pathway GO:0030509 9.76 TGFB1 SMAD3 BMP6
17 cell-cell junction organization GO:0045216 9.75 TGFB1 SMAD3
18 positive regulation of SMAD protein signal transduction GO:0060391 9.73 TGFB1 BMP6
19 cellular response to virus GO:0098586 9.73 TGFB1 SMAD3 H19
20 SMAD protein signal transduction GO:0060395 9.72 TGFB1 SMAD3 BMP6
21 positive regulation of reactive oxygen species biosynthetic process GO:1903428 9.71 CD36 H19
22 lens fiber cell differentiation GO:0070306 9.69 TGFB1 SMAD3
23 positive regulation of vascular permeability GO:0043117 9.67 TGFB1 BMP6
24 regulation of striated muscle tissue development GO:0016202 9.67 TGFB1 SMAD3
25 SMAD protein complex assembly GO:0007183 9.58 SMAD3 TGFB1
26 regulation of binding GO:0051098 9.46 TGFB1 SMAD3
27 positive regulation of extracellular matrix assembly GO:1901203 9.43 TGFB1 SMAD3
28 positive regulation of bone mineralization GO:0030501 9.35 TGFB1 SMAD3 BMP6
29 regulation of miRNA transcription GO:1902893 8.8 TGFB1 SMAD3

Molecular functions related to Keloid Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transforming growth factor beta receptor binding GO:0005160 8.8 TGFB1 SMAD3

Sources for Keloid Disorder

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....